South Korea Recombinant Proteins Market (2023-2028)
The South Korea Recombinant Proteins Market was valued at $14 Million in 2023 and projected to reach to $18.8 Million by 2028, representing a compound annual growth rate of 6.0%. South Korea's recombinant proteins market is poised for steady growth through 2028, supported by the country's advanced biotechnology ecosystem and increasing investment in biopharmaceutical research and development.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
South Korea Recombinant Proteins Market Trends and Insights
- South Korea's advanced biotechnology infrastructure and strong pharmaceutical sector position the country as a key player in recombinant protein development and commercialization across Asia Pacific.
- The market in South Korea is driven by increasing demand for biologics, rising prevalence of chronic diseases, and significant investment in research and development by both government and private entities. South Korea's healthcare system continues to prioritize innovative therapeutic solutions, creating favorable conditions for recombinant protein adoption.
- South Korea's regulatory framework supports expedited approval pathways for biopharmaceuticals, enabling faster market entry for novel recombinant protein therapies.
- Between 2023 and 2028, South Korea is expected to see sustained growth fueled by expanding manufacturing capabilities, growing clinical applications, and increasing healthcare expenditure..
Key Market Statistics
- CAGR (2023-2028) 6.0% CAGR
- Market Size, 2023 ~USD 14 Million
- Forecast, 2028 ~USD 18.8 Million
- Country South Korea
South Korea Recombinant Proteins Market Overview
Market Valuation Growth :
South Korea's recombinant proteins market reached $14.0 million in 2023 and is expected to expand to $18.8 million by 2028, driven by increasing demand for biopharmaceuticals and therapeutic proteins in the region.
Biotechnology Infrastructure :
South Korea possesses advanced biotechnology infrastructure and research capabilities, positioning it as a regional hub for recombinant protein development, manufacturing, and commercialization across Asia Pacific.
Pharmaceutical Sector Strength :
The country's robust pharmaceutical sector and government support for biotech innovation create favorable conditions for recombinant protein market expansion and investment in protein-based therapeutics.
Regional Market Position :
South Korea serves as a key player in Asia Pacific's recombinant proteins landscape, with growing adoption of biologics and increasing healthcare expenditure supporting market growth at a 6.0% CAGR through 2028.
South Korea Recombinant Proteins Market Dynamics
- The market's 6.0% CAGR reflects growing demand for protein-based therapeutics, including monoclonal antibodies, growth factors, and recombinant enzymes used in treating chronic diseases and cancer. Government initiatives promoting biotech innovation, coupled with South Korea's skilled workforce and manufacturing capabilities, will drive market expansion.
- Rising healthcare spending, aging population demographics, and increased adoption of biologics in clinical practice are expected to accelerate recombinant protein commercialization.
- Strategic partnerships between domestic biotech firms and international pharmaceutical companies will further strengthen South Korea's position as a regional leader in recombinant protein development and production..
Market Ecosystem
RECOMBINANT PROTEINS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Recombinant cytokines and growth factors from its Gibco, Invitrogen, and PeproTech brands are used in cell culture, drug discovery, immunology research, stem cell expansion, and cell therapy manufacturing. Its GMP-grade proteins support the production of cell-based therapies. | Supports reproducible cell culture and immune-cell expansion | Enables research-to-manufacturing workflows | Supports clinical manufacturing requirements through GMP-grade proteins. |
 |
Merck provides recombinant protein expression and process-development technologies for biopharmaceutical applications. Its CHOZN expression platform and associated process-development services support the development and scale-up of recombinant proteins and other biologics. | Supports high-producing cell-line development | Facilitates process optimization and scale-up | Helps improve manufacturing productivity and consistency. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- South Korea's recombinant proteins market is valued at $14.0 million in 2023 with projected growth to $18.8 million by 2028.
- South Korea demonstrates a 6.0% CAGR, reflecting steady expansion driven by biotechnology advancement and healthcare innovation.
- South Korea's robust regulatory environment and manufacturing infrastructure support rapid commercialization of recombinant protein therapies.
- South Korea's growing chronic disease burden and increased R&D investment are key catalysts for market expansion through 2028.
Recombinant Proteins Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2023 |
| Fastest Growing Segment | INTERFERONS (IFNS) (Type) |
| Forecast Period | 2023-2028 |
| Growth Rate | CAGR of 7.2% from 2023 to 2028 |
| Largest Segment | PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES (End User) |
| Market Size Base Year (Billions) | ~USD 2.26 (2023) |
| Revenue Forecast (Billions) | ~USD 3.2 (2028) |
| Segments Covered | Product, Type, Application, Host Cell, End User |
South Korea Recombinant Proteins Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product
- Adhesion Molecules & Receptors
- Growth Factors & Chemokines
- Immune Response Proteins
- Kinase Proteins
- Membrane Proteins
- Other Recombinant Proteins
- Recombinant Metabolic Enzymes
- Regulatory Proteins
- Structural Proteins
By Type
- Academic Research
- Biologics
- Biotechnology Research
- Cell & Gene Therapy
- Interferons (Ifns)
- Interleukins (Ils)
- Other Growth Factors & Chemokines
- Vaccines
By Application
- Biopharmaceutical Production
- Diagnostics
- Drug Discovery & Development
- Other Applications
- Research
By Host Cell
- Bacterial Cells
- Insect Cells
- Mammalian Systems
- Other Cell Hosts
- Other Host Cells
- Yeast & Fungi
By End User
- Academic Research Institutes
- Biotechnology Companies
- Contract Research Organizations
- Other End Users
- Pharmaceutical & Biopharmaceutical Companies
Target Audience
- Biopharmaceutical Companies : South Korean and international biotech firms need market-specific data to assess market potential, identify local partnerships, and develop commercialization strategies for recombinant protein products in Korea.
- Healthcare Investors & Venture Capitalists : Investment firms targeting South Korea's biotech sector require detailed market sizing and growth forecasts to evaluate funding opportunities in recombinant protein development and manufacturing ventures.
- Contract Manufacturing Organizations (CMOs) : CMOs and contract research organizations need South Korea market intelligence to understand demand for recombinant protein manufacturing services and identify expansion opportunities in the region.
- Pharmaceutical Regulatory Bodies : South Korean regulatory agencies and healthcare authorities require market data to inform policy decisions, biotech incentive programs, and strategic planning for the recombinant proteins sector.
- Market Research & Consulting Firms : Research organizations and consultants need country-specific market data to support client advisory services, competitive analysis, and strategic recommendations for stakeholders in South Korea's biotech industry.
Reasons to Buy this Report
- Market-Specific Sizing & Forecasts : Access precise valuation data for South Korea's recombinant proteins market with detailed 2023-2028 projections, enabling accurate financial planning and investment decisions tailored to this specific regional market.
- Competitive Landscape Intelligence : Understand South Korea's unique biotechnology ecosystem, key players, manufacturing capabilities, and regulatory environment to identify partnership opportunities and competitive positioning within the region.
- Growth Driver Analysis : Gain insights into South Korea-specific factors driving market expansion, including government biotech initiatives, healthcare spending trends, and adoption of protein-based therapeutics in clinical practice.
- Regional Strategic Planning : Develop targeted market entry and expansion strategies for South Korea by leveraging country-specific data on demand patterns, distribution channels, and emerging opportunities in the recombinant proteins sector.
- Investment & Funding Decisions : Make informed investment decisions regarding South Korean biotech ventures, manufacturing facilities, and R&D collaborations with comprehensive market intelligence and growth trajectory analysis.
Frequently asked questions
What is the current market size of recombinant proteins in South Korea?
South Korea's recombinant proteins market was valued at $14.0 million in 2023 and is expected to reach $18.8 million by 2028.
What is the projected growth rate for South Korea's recombinant proteins market?
South Korea's recombinant proteins market is projected to grow at a compound annual growth rate (CAGR) of 6.0% from 2023 to 2028.
What factors are driving growth in South Korea's recombinant proteins market?
South Korea's market growth is driven by advanced biotechnology infrastructure, rising chronic disease prevalence, strong government and private R&D investment, and supportive regulatory frameworks for biopharmaceuticals.
How does South Korea's recombinant proteins market compare to other Asia Pacific countries?
South Korea maintains a competitive position in Asia Pacific due to its advanced manufacturing capabilities, skilled workforce, and innovation-focused healthcare system supporting recombinant protein development.
What regulatory advantages does South Korea offer for recombinant protein companies?
South Korea's regulatory framework includes expedited approval pathways for biopharmaceuticals, enabling faster market entry and commercialization of novel recombinant protein therapies.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global recombinant proteins market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
The secondary sources referred to for this research study include publications from government sources,such as the World Health Organization, The Antibody Society,Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC),National Center for Biotechnology Information (NCBI), American Medical Association (AMA), RecombinantAntibody Network (RAN), National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), and the Institute for Molecular Medicine, corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, professional associations, and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the recombinant proteins market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data were triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Recombinant proteins are manipulated proteins generated by recombinant DNA technology that modifies gene sequences. These are formed by transfecting foreign genes into a host cell. Recombinant proteins are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses. This market includes recombinant protein products, including growth factors, cytokines, recombinant enzymes, structural proteins, and membrane proteins.
Key Stakeholders
- Pharmaceutical & Biopharmaceutical Companies
- Biotechnology Companies
- Life Sciences Companies
- Academic Research Institutes
- Government Institutes
- Private Research Firms
- Contract Research Organizations (CROs)
- Third-party Suppliers, Direct Suppliers, Distributors, and Channel Partners
- Venture Capitalists and Investors
- Market Research and Consulting Firms
Report Objectives
- To define, describe, and forecast the recombinant proteins market based on product, host cell, application, and end user
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall recombinant proteins market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the recombinant proteins market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the recombinant proteins market
- To benchmark players within the recombinant proteins market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
- Further breakdown of the Rest of Europe recombinant proteins market, by country
- Further breakdown of the Rest of Asia Pacific recombinant proteins market, by country
- Further breakdown of the Rest of Latin America recombinant proteins market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Get the Full Recombinant Proteins Market Report
Full forecast, segment splits, and company analysis for all Recombinant Proteins Market.
- Canada Recombinant Proteins Market
- US Recombinant Proteins Market
- Germany Recombinant Proteins Market
- UK Recombinant Proteins Market
- France Recombinant Proteins Market
- Italy Recombinant Proteins Market
- Spain Recombinant Proteins Market
- China Recombinant Proteins Market
- Japan Recombinant Proteins Market
- India Recombinant Proteins Market
- Brazil Recombinant Proteins Market
- Rest Of Europe Recombinant Proteins Market
- United Kingdom Recombinant Proteins Market
- Rest Of Asia Pacific Recombinant Proteins Market
- Rest Of Latin America Recombinant Proteins Market
- GCC Countries Recombinant Proteins Market
- Rest Of The Middle East Recombinant Proteins Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
